Rivastigmine for vascular cognitive impairment

Area of Science:

• Neurology
• Pharmacology

Background:

• Vascular dementia is the second leading cause of dementia, encompassing multi-infarct, single strategic infarct, and subcortical dementia.
• Vascular cognitive impairment (VCI) is a more encompassing term for cognitive deficits without memory loss, for which no standard treatment exists.
• Reduced acetylcholine activity in VCI suggests potential efficacy of cholinesterase inhibitors, similar to Alzheimer's disease.

Purpose of the Study:

• To evaluate the effectiveness of rivastigmine in treating individuals with vascular cognitive impairment, vascular dementia, or mixed dementia.

Main Methods:

• Searched the Cochrane Dementia and Cognitive Improvement Group's Specialized Register for randomized, double-blind, placebo-controlled trials of rivastigmine.
• Included trials comparing rivastigmine with placebo, identified through specific search terms.

Main Results:

• No suitable trials were found to perform a meta-analysis.
• Some indication of rivastigmine's benefit in cognitive and non-cognitive domains was noted in other identified trials.

Conclusions:

• Existing data suggest potential benefits of rivastigmine for VCI, but this is based on small, non-placebo-controlled, or extrapolated studies.
• Large, well-designed, placebo-controlled trials are required to establish rivastigmine's efficacy in VCI.
• Future trial methodologies should address the unique characteristics of VCI and its subtypes.